• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Microscopic Modes and Free Energies for Topoisomerase I-DNA Covalent Complex Binding with Non-campothecin Inhibitors by Molecular Docking and Dynamics Simulations.通过分子对接和动力学模拟研究拓扑异构酶I-DNA共价复合物与非喜树碱抑制剂结合的微观模式和自由能
Theor Chem Acc. 2013 Aug;132(8). doi: 10.1007/s00214-013-1379-z.
2
SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin.SUMO-1与完整的DNA拓扑异构酶I的缀合增强了喜树碱诱导的可裂解复合物的形成。
Oncogene. 2002 Nov 14;21(52):7913-22. doi: 10.1038/sj.onc.1205917.
3
Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction.Y盒结合蛋白1通过直接相互作用增强DNA拓扑异构酶1的活性及对喜树碱的敏感性。
J Exp Clin Cancer Res. 2014 Dec 24;33(1):112. doi: 10.1186/s13046-014-0112-7.
4
Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.三嗪衍生物作为ROCK1抑制剂的发现与优化:分子对接、分子动力学模拟及自由能计算
Mol Biosyst. 2013 Mar;9(3):361-74. doi: 10.1039/c2mb25408e. Epub 2013 Jan 23.
5
Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.计算确定磷酸二酯酶-2 与苯并[1,4]二氮杂卓-2-酮衍生物的结合结构和自由能。
J Phys Chem B. 2010 Dec 9;114(48):16020-8. doi: 10.1021/jp1086416. Epub 2010 Nov 15.
6
Computational determination of binding structures and free energies of glucose 6-phosphate dehydrogenase with novel steroid inhibitors.新型甾体抑制剂与6-磷酸葡萄糖脱氢酶结合结构及自由能的计算测定
J Mol Graph Model. 2014 Jun;51:168-72. doi: 10.1016/j.jmgm.2014.05.009. Epub 2014 Jun 2.
7
Characterization of DNA topoisomerase-1 in Spodoptera exigua for toxicity evaluation of camptothecin and hydoxy-camptothecin. characterization of DNA topoisomerase-1 in spodoptera exigua for toxicity evaluation of camptothecin and hydroxy-camptothecin.
PLoS One. 2013;8(2):e56458. doi: 10.1371/journal.pone.0056458. Epub 2013 Feb 22.
8
Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells.芹菜素直接与结肠癌细胞上的拓扑异构酶1相互作用并抑制该酶,从而上调CD26/二肽基肽酶4。
Front Pharmacol. 2022 Dec 22;13:1086894. doi: 10.3389/fphar.2022.1086894. eCollection 2022.
9
Molecular Modeling Studies of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors through Receptor-Based 3D-QSAR and Molecular Dynamics Simulations.基于受体的3D-QSAR和分子动力学模拟对11β-羟基类固醇脱氢酶1型抑制剂的分子建模研究
Molecules. 2016 Sep 19;21(9):1222. doi: 10.3390/molecules21091222.
10
Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.新型漆酚衍生物作为 HDAC8 抑制剂的研究:合理设计、虚拟筛选、分子对接和分子动力学研究。
J Biomol Struct Dyn. 2018 Jun;36(8):1966-1978. doi: 10.1080/07391102.2017.1344568. Epub 2017 Jul 6.

本文引用的文献

1
Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.用于癌症治疗的新型非喜树碱拓扑异构酶 I 抑制剂 Genz-644282。
Clin Cancer Res. 2011 May 1;17(9):2777-87. doi: 10.1158/1078-0432.CCR-10-0542. Epub 2011 Mar 17.
2
3-Arylisoquinolines as novel topoisomerase I inhibitors.3-芳基异喹啉类作为新型拓扑异构酶 I 抑制剂。
Bioorg Med Chem. 2011 Jan 15;19(2):724-34. doi: 10.1016/j.bmc.2010.10.057. Epub 2010 Nov 2.
3
Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents.设计、合成并评价二苯并[c,h][1,6]萘啶类化合物作为拓扑异构酶 I 抑制剂和潜在的抗癌药物。
J Med Chem. 2010 Dec 23;53(24):8716-26. doi: 10.1021/jm101048k. Epub 2010 Nov 23.
4
Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.计算确定磷酸二酯酶-2 与苯并[1,4]二氮杂卓-2-酮衍生物的结合结构和自由能。
J Phys Chem B. 2010 Dec 9;114(48):16020-8. doi: 10.1021/jp1086416. Epub 2010 Nov 15.
5
Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.基于结构的虚拟筛选和埃坡霉素衍生物作为抗肿瘤剂的命中优化选择埃坡霉素为新型拓扑异构酶 I 抑制剂。
J Med Chem. 2010 Nov 11;53(21):7521-31. doi: 10.1021/jm100387d.
6
Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.拓扑替康作为一种分子靶向药物,可阻断铂类耐药卵巢癌中的 Akt 和 VEGF 级联反应。
Cancer Biol Ther. 2010 Dec 1;10(11):1137-46. doi: 10.4161/cbt.10.11.13443.
7
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.口服拓扑替康节拍疗法联合抗血管生成药物帕唑帕尼治疗卵巢癌的强大临床前影响。
Mol Cancer Ther. 2010 Apr;9(4):996-1006. doi: 10.1158/1535-7163.MCT-09-0960. Epub 2010 Apr 6.
8
Understanding microscopic binding of human microsomal prostaglandin E synthase-1 (mPGES-1) trimer with substrate PGH2 and cofactor GSH: insights from computational alanine scanning and site-directed mutagenesis.理解人微粒体前列腺素 E 合酶-1(mPGES-1)三聚体与底物 PGH2 和辅因子 GSH 的微观结合:来自计算丙氨酸扫描和定点突变的见解。
J Phys Chem B. 2010 Apr 29;114(16):5605-16. doi: 10.1021/jp100668y.
9
Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation.通过分子建模、对接和动力学模拟确定人磷酸二酯酶-2的结合态结构及其与抑制剂的结合情况。
J Phys Chem B. 2009 Mar 5;113(9):2896-908. doi: 10.1021/jp8082612.
10
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.DNA拓扑异构酶I抑制剂:化学、生物学及界面抑制
Chem Rev. 2009 Jul;109(7):2894-902. doi: 10.1021/cr900097c.

通过分子对接和动力学模拟研究拓扑异构酶I-DNA共价复合物与非喜树碱抑制剂结合的微观模式和自由能

Microscopic Modes and Free Energies for Topoisomerase I-DNA Covalent Complex Binding with Non-campothecin Inhibitors by Molecular Docking and Dynamics Simulations.

作者信息

Wei Ning-Ning, Hamza Adel, Hao Ce, Xiu Zhilong, Zhan Chang-Guo

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, Kentucky 40536 ; State Key Laboratory of Fine Chemicals, School of Life Science and Biotechnology, Dalian University of Technology, Dalian 116024, China.

Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, Kentucky 40536.

出版信息

Theor Chem Acc. 2013 Aug;132(8). doi: 10.1007/s00214-013-1379-z.

DOI:10.1007/s00214-013-1379-z
PMID:24363608
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3867144/
Abstract

Topoisomerase I (Topo1) has been identified as an attractive target for anticancer drug development due to its central role in facilitating the nuclear process of the DNA. It is essential for rational design of novel Topo1 inhibitors to reliably predict the binding structures of the Topo1 inhibitors interacting with the Topo1-DNA complex. The detailed binding structures and binding free energies for the Topo1-DNA complex interacting with typical non-camptothecin (CPT) Topo1 inhibitors have been examined by performing molecular docking, molecular dynamic (MD) simulations, and binding free energy calculations. The computational results provide valuable insights into the binding modes of the inhibitors binding with the Topo1-DNA complex and the key factors affecting the binding affinity. It has been demonstrated that the - stacking interaction with the DNA base pairs and the hydrogen bonding with Topo1 have the pivotal contributions to the binding structures and binding free energies, although the van der Waals and electrostatic interactions also significantly contribute to the stabilization of the binding structures. The calculated binding free energies are in good agreement with the available experiment activity data. The detailed binding modes and the crucial factors affecting the binding free energies obtained from the present computational studies may provide valuable insights for future rational design of novel, more potent Topo1 inhibitors.

摘要

拓扑异构酶I(Topo1)因其在促进DNA核过程中的核心作用,已被确定为抗癌药物开发的一个有吸引力的靶点。可靠地预测与Topo1-DNA复合物相互作用的Topo1抑制剂的结合结构,对于新型Topo1抑制剂的合理设计至关重要。通过进行分子对接、分子动力学(MD)模拟和结合自由能计算,研究了与典型非喜树碱(CPT)Topo1抑制剂相互作用的Topo1-DNA复合物的详细结合结构和结合自由能。计算结果为抑制剂与Topo1-DNA复合物的结合模式以及影响结合亲和力的关键因素提供了有价值的见解。结果表明,与DNA碱基对的π-堆积相互作用以及与Topo1的氢键对结合结构和结合自由能起关键作用,尽管范德华力和静电相互作用对结合结构的稳定也有显著贡献。计算得到的结合自由能与现有的实验活性数据吻合良好。从目前的计算研究中获得的详细结合模式和影响结合自由能的关键因素,可能为未来新型、更有效的Topo1抑制剂的合理设计提供有价值的见解。